AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ETOCALA, Fla., June 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or t

AIM ImmunoTechJun 2 23:00

AIM ImmunoTech Announces $2 Million Registered Direct Release Pricing

AIM ImmunoTech Announces $2 Million Registered Direct Release Pricing

Zhitong FinanceMay 31 07:30

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

OCALA, Fla., May 31, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional in

AIM ImmunoTechMay 30 23:00

AIM ImmunoTech Inc.: Ascendiant Capital Markets raised the target price from $5 to 5.

AIM ImmunoTech Inc.: Ascendiant Capital Markets raised the target price from $5 to 5.

Zhitong FinanceMay 23 23:58

Express News | AIM ImmunoTech Inc : Ascendiant Capital Markets Raises Target Price to $5.25 From $5

BreakingsMay 23 23:58

Buy Rating Affirmed: AIM ImmunoTech's Ampligen Shows Promising Oncology Pipeline Progress

TipRanksMay 17 12:55